Main news

 


 

Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss
Novel GLP-1 Agonist Promotes Safe and Effective Weight Loss Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data from more than 600 individuals.


The New Playbook for Ditching Dangerous Senior Meds
The New Playbook for Ditching Dangerous Senior Meds A new tool presented at the American Geriatrics Society (AGS) 2025 Annual Scientific Meeting may give clinicians practical and safer alternatives to risky medications for patients.


Editorial Activity

cardiology book

Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis
Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis Immune checkpoint inhibitors (ICIs) are successful in treating many cancers but may cause immune-related adverse events. ICI-mediated myocarditis has a high fatality rate with severe cardiovascular consequences. Targeted therapies for ICI myocarditis are currently limited. Bill is developing a new therapeutic approach targeting CXCR3 for the treatment of myocarditis with immunotherapy.


Ross Procedure Making a Comeback in Aortic Valve Disease
Ross Procedure Making a Comeback in Aortic Valve Disease The Ross procedure, which can be used to treat young people with severe aortic valve disease, has seen wide swings in popularity over the years, but now, with consistent data on long-term survival and valve durability, numbers are steadily climbing again.


AHA Advisory Endorses Endovascular Thrombectomy for Large Core Ischemic Stroke
AHA Advisory Endorses Endovascular Thrombectomy for Large Core Ischemic Stroke Results of six recent trials of endovascular thrombectomy (EVT) for patients with large-core ischemic stroke (LCIS) provide strong evidence for the benefit of this intervention compared with medical management (MM), a new Science Advisory from the American Heart Association (AHA) has concluded.


AI-Enhanced ECG Predicts Hypertension, Related Risks
AI-Enhanced ECG Predicts Hypertension, Related Risks An artificial intelligence–ECG risk estimation model designed to predict incident hypertension (AIRE-HTN) identifies cases and stratifies the risk for adverse outcomes in addition to traditional markers.


CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards
CGM Use, GLP-1s, Drinking Water Key of 2025 ADA Standards The American Diabetes Association (ADA)’s Standards of Care — 2025 offer new guidance on broader use of continuous glucose monitoring (CGM), use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) beyond weight loss, management of metabolic dysfunction-associated liver disease (MAFLD), plus a strong endorsement for drinking water and much more.


ADA Advises Against Using Compounded GLP-1 RA Medications
ADA Advises Against Using Compounded GLP-1 RA Medications In a new statement, the American Diabetes Association (ADA) has advised against the use of compounded glucagon-like peptide 1 receptor agonist (GLP-1 RA) and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RA medication classes.


New Trial Result Pushes Past Antiarrhythmic Therapy After MI
New Trial Result Pushes Past Antiarrhythmic Therapy After MI For ventricular tachycardia after myocardial infarction, outcomes are better with upfront catheter ablation than drug therapy, which is typically used first, the multinational VANISH2 trial shows.


New Pill Successfully Lowers Lp(a) Levels
New Pill Successfully Lowers Lp(a) Levels Muvalaplin, a novel oral medication, safely and effectively lowers high levels of lipoprotein(a), or Lp(a), results from the phase 2 KRAKEN trial show.